Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
GSK-2881078 is a nonsteroidal selective androgen receptor modulator (SARM) of the indole-5-carbonitrile chemotype, developed by GlaxoSmithKline to produce tissue-selective anabolic effects in skeletal muscle with reduced activity in androgen-sensitive tissues. It has been studied in three human clinical trials (Phase I and Phase IIa) but has never been approved for any indication and is not in active further development. SARMs as a pharmacological class are prohibited in sport at all times under WADA category S1.2 (Other Anabolic Agents), though GSK-2881078 is not individually named in reviewed WADA documents.
0 of 1 vendors lab-verified
Verified purity per dollar — the cheapest that's actually been tested
No prices found for GSK-2881078.
Single-vial list prices by default for a fair head-to-head — switch to Multi-vial / bulk for pack pricing. Estimates only; verify at vendor before purchase. For research use only. Not medical advice.
Kimera Chems has the lowest single-vial GSK-2881078 price at $0.077/mg among 3 COA-verified vendors on Disclosed Labs. Bulk or multi-vial deals may be lower.
What is the price range for GSK-2881078?
Research-grade GSK-2881078 is listed at $0.077/mg from 1 verified source on Disclosed Labs.
How are GSK-2881078 prices verified on Disclosed Labs?
Every listed vendor holds a Grade C or better trust score, computed independently from lab Certificates of Analysis — not from payments or sponsorships. Prices are scraped and fact-checked daily. Vendors cannot pay to improve their ranking.
Check formulation: Lyophilized powder requires reconstitution before use. Pre-mixed solutions are more convenient but may have a shorter shelf life and higher prices.
Compare per-mg cost: Different strengths and quantities make direct price comparison difficult. Calculate the per-milligram cost to find the true best value.
Verify COAs: Look for vendors that publish per-batch Certificates of Analysis from named, accredited labs. Use the Full safety panel filter to require endotoxin, sterility, and heavy-metals testing on the current batch — not just HPLC purity.
Human data are the most extensive of any compound in the SARM class: a Phase I first-in-human study in healthy men and postmenopausal women (Clark 2017) established dose-proportional systemic exposure and a long half-life (>100 hours) supporting once-daily dosing; a Phase I dose-escalation study in adults ≥50 years (Neil 2018) showed dose-dependent lean body mass gains (~3.39 kg in women, ~1.76 kg in men versus placebo at 8 weeks) accompanied by transient ALT elevations and 30–45% HDL-cholesterol reductions at the highest doses, both reversible on stopping treatment; and a Phase IIa randomized controlled trial in 97 COPD patients with muscle weakness (Mohan 2023) demonstrated increased lean body mass and leg-press strength (more consistently in men) over 13 weeks, with reversible HDL-C reduction and transient ALT increases as the main treatment-related safety signals. No peer-reviewed animal or in-vitro pharmacology/toxicology data for GSK-2881078 were located via PubMed or PubChem.
This platform provides informational tools only, not medical advice.
Safety, pharmacokinetics and pharmacological effects of the selective androgen receptor modulator, GSK2881078, in healthy men and postmenopausal women
2017
GSK2881078, a SARM, Produces Dose-Dependent Increases in Lean Mass in Healthy Older Men and Women
2018
Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: a randomised control trial
Prices verified as of July 2026. Actual prices may vary. For research use only.
2023
Disclosed Labs